<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hyperkinetic movement disorders in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hyperkinetic movement disorders in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hyperkinetic movement disorders in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Jankovic, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 09, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Movement disorders are characterized by either excessive (hyperkinetic) or reduced (bradykinetic) activity. Hyperkinetic disorders are reviewed here. Bradykinetic disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6231.html" rel="external">
          "Bradykinetic movement disorders in children"
         </a>
         .)
        </p>
        <p>
         Hyperkinetic disorders are characterized by abnormal involuntary movement. These excess movements can be regular and rhythmic, as in tremor; more sustained and patterned, as in dystonia; brief and random, as in chorea; or jerk-like and temporarily suppressible, as in tics. Diagnosis of the specific condition depends primarily upon careful observation of the clinical features [
         <a href="#rid1">
          1
         </a>
         ]. Tics are the most common hyperkinetic disorder in children. Dystonia, stereotypies, choreoathetosis, tremors, and myoclonus also occur but are less common. Many hyperkinetic movement disorders manifest with multiple types of movements, which may include a combination of the various hyperkinesias.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANATOMY OF THE BASAL GANGLIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A brief review of the anatomy of the basal ganglia is appropriate since this site is involved in many of the bradykinetic disorders. The basal ganglia regulate the initiation, scaling, and control of the amplitude and direction of movement. Movement disorders can result from biochemical or structural abnormalities in these structures.
        </p>
        <p>
         The basal ganglia are a complex of deep nuclei that consist of the corpus striatum, globus pallidus, and substantia nigra. The corpus striatum, which includes the caudate nucleus and the putamen, receives input from the cerebral cortex and the thalamus and, in turn, projects to the globus pallidus.
        </p>
        <p>
         The substantia nigra is divided into the dopamine-rich pars compacta and the less dense pars reticularis. The pars reticularis is similar histologically and chemically to the medial segment of the globus pallidus, and both project via the thalamus to the premotor and motor cortex. The substantia nigra pars compacta gives rise to the nigral-striatal pathway, which is the main dopaminergic tract.
        </p>
        <p>
         The output of the basal ganglia projects by way of the thalamus to the cerebral cortex and then to the pyramidal system. Basal ganglia output is sometimes referred to as the extrapyramidal system because it was formerly thought to be in parallel with the pyramidal system. Integration of the basal ganglia with the cortex facilitates motor control.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          TIC DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As defined by the Taskforce on Childhood Movement Disorders, "tics are repeated, individually recognizable, intermittent movements or movement fragments that are almost always briefly suppressible and are usually associated with awareness of an urge to perform the movement" [
         <a href="#rid2">
          2,3
         </a>
         ]. Tics manifest as sudden, brief intermittent movements (motor tics) or utterances (vocal or phonic tics). Although tics can be voluntarily controlled for short periods of time, it is difficult to suppress tics for sustained periods of time. In some cases, tics can be so intense that they result in self-injury [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Transient tics last less than one year, whereas most with childhood-onset tics continue to have tics or have recurrence of the tics several years later. Persistent motor and phonic tics are features of Tourette syndrome, as described below  (
         <a class="graphic graphic_table graphicRef61505" href="/z/d/graphic/61505.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Secondary causes should be considered in individuals in whom tics begin abruptly, are persistent, or are particularly problematic. Secondary causes of tics include the use of stimulant medications (dopaminergic agonists). Another potential but controversial cause is pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS). (See
         <a class="medical medical_review" href="/z/d/html/8046.html" rel="external">
          "Complications of streptococcal tonsillopharyngitis", section on 'PANDAS syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4232478833">
         <span class="h2">
          Provisional tic disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Provisional tic disorder, which has replaced the term "transient tic disorder" in the DSM-5 classification, specifies that tics have been present for less than one year  (
         <a class="graphic graphic_table graphicRef61505" href="/z/d/graphic/61505.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Transient tics occur in up to 10 percent of otherwise healthy children and may spontaneously remit in a few weeks or months [
         <a href="#rid5">
          5,6
         </a>
         ]. Most children with simple motor tics do not require treatment.
        </p>
        <p>
         There is growing evidence that once tics begin, they usually persist, certainly beyond one year and in many cases for a lifetime. One study identified several clinical features present at the first examination that predict persistence of tics after one year, including higher baseline tic severity, mild autism spectrum symptoms, and the presence of anxiety disorder [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Of note, an increase in functional tics has been seen during the coronavirus disease 2019 (COVID-19) pandemic, primarily affecting adolescent females and associated with complex, large-amplitude motor tics and a wide range of vocal utterances [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14132.html" rel="external">
          "Functional movement disorders", section on 'Functional tics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Tourette syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tourette syndrome is reviewed here briefly and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6221.html" rel="external">
          "Tourette syndrome: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Tourette syndrome is a common movement and neurobehavioral disorder in children. The hallmark of Tourette syndrome is the occurrence of multiple motor and vocal (phonic) tics. Tics in Tourette syndrome may be simple, involving a single muscle or muscle group, or complex, involving sequential, coordinated movements. Simple tics include blinking, facial grimacing, shoulder shrugging, and head jerking. Complex tics include bizarre gait, kicking, jumping, body gyrations, and seductive or obscene gestures. Involuntary vocalizations may include simple noises to more complex utterances such as coprolalia (shouting of obscenities or profanities), echolalia (repeating what others say), and palilalia (repeating the patient's own words or phrases).
        </p>
        <p>
         There is growing evidence that transient tic and persistent motor and phonic tics represent a continuum rather than separate disorders [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DYSTONIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definition of dystonia, as updated in 2013 by an international consensus committee of movement disorder experts, is as follows [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dystonic movements are typically patterned, twisting, and may be tremulous
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dystonia is often initiated or worsened by voluntary action and associated with overflow muscle activation
        </p>
        <p>
        </p>
        <p>
         The consensus committee also updated the classification system for dystonia  (
         <a class="graphic graphic_table graphicRef59278" href="/z/d/graphic/59278.html" rel="external">
          table 2
         </a>
         ), basing it upon clinical characteristics and etiology [
         <a href="#rid10">
          10
         </a>
         ]. The clinical characteristics include age at onset, body distribution, temporal pattern, coexistence of other movement disorders, and other neurologic manifestations. The etiologic characteristics are the presence or absence of nervous system pathology and the pattern of inheritance.
        </p>
        <p>
         Historically, dystonia was classified as primary, secondary, or psychogenic depending upon the cause. By definition, primary dystonia (formerly known as dystonia musculorum deformans or idiopathic torsion dystonia) was associated with no other neurologic impairment, such as intellectual, pyramidal, cerebellar, or sensory deficits. However, tremor that appears identical to essential tremor occurs in approximately 20 percent of patients with this condition. In some families, dystonia and essential tremor coexist. (See
         <a class="local">
          'Essential tremor'
         </a>
         below.)
        </p>
        <p>
         Cerebral palsy is probably the most common cause of acquired dystonia  (
         <a class="graphic graphic_table graphicRef51622" href="/z/d/graphic/51622.html" rel="external">
          table 3
         </a>
         ) seen in children [
         <a href="#rid11">
          11
         </a>
         ]. Other causes of childhood dystonia  (
         <a class="graphic graphic_table graphicRef70477" href="/z/d/graphic/70477.html" rel="external">
          table 4
         </a>
         ) include a variety of heredodegenerative disorders such as Wilson disease and neurodegeneration with brain iron accumulation [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Neurodegeneration with brain iron accumulation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The onset of involuntary movements occurs before age 20 in approximately 30 percent of patients with dystonia. The distribution of the affected muscle groups appears to depend upon age. The disorder typically begins distally in children, whereas a cranial-cervical distribution is more common in adults. Childhood dystonia usually progresses to a generalized disorder, whereas adult dystonia usually remains focal or segmental [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         The range of severity of dystonia is variable and may depend upon the situation. As an example, some patients have task-specific dystonias that occur only when they participate in certain activities, such as writing, typing, or playing the piano ("musician's hands") [
         <a href="#rid14">
          14
         </a>
         ]. As the dystonia worsens, it typically extends to adjacent muscles and eventually occurs even at rest. In rare cases, the spasms become severe and may cause cervical disc, nerve, or root problems [
         <a href="#rid15">
          15
         </a>
         ]. Muscle breakdown with myoglobinuria ("dystonic storm") also can occur [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         No specific morphologic changes have been noted in neuropathologic examinations of patients with isolated dystonia [
         <a href="#rid17">
          17
         </a>
         ]. Rather, functional imaging studies provide evidence that dystonia is a network disease involving connections between the basal ganglia, cerebellum, and brainstem [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H52701546">
         <span class="h3">
          Hemidystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemidystonia (also known as unilateral dystonia) involves one-half of the body and occurs frequently in children and young adults. In a retrospective series of 33 patients with hemidystonia, approximately 60 percent of patients had a structural lesion in the contralateral basal ganglia, often the putamen, that resulted from an insult to the brain [
         <a href="#rid20">
          20
         </a>
         ]. The most common etiologies were infarction or hemorrhage (30 percent), perinatal injury (27 percent), and trauma (24 percent). Hemidystonia often presented several years after the precipitating factor; this delay occurred more often in children.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early-onset generalized isolated dystonia (previously called primary dystonia) may be sporadic or inherited. Cases with onset in childhood usually are inherited in an autosomal dominant pattern  (
         <a class="graphic graphic_table graphicRef70477" href="/z/d/graphic/70477.html" rel="external">
          table 4
         </a>
         ). Many hereditary cases are caused by a defect in torsinA, a protein with uncertain function that is expressed in the brain. A rare cause of hereditary dystonia is dopa-responsive dystonia. The number of gene variants associated with dystonia has been expanding at an exponential pace, and genetic classification and nomenclature are continuously evolving [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          DYT1 dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with inherited dystonia have a pathogenic variant in the TOR1A (
         <em>
          DYT1
         </em>
         ) gene that encodes the protein torsinA, an adenosine triphosphate (ATP)-binding protein in the 9q34 locus. DYT1 dystonia is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'DYT-TOR1A dystonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Dopa-responsive dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dopa-responsive dystonia (DRD) is an unusual form of inherited progressive dystonia that begins during the first decade after birth. The dystonia usually starts in the legs and becomes generalized. Some patients may also have hyperreflexia, rigidity, tremor, and other parkinsonian features, and less commonly, cerebellar signs. The most frequent form of DRD is autosomal dominant DYT5 dystonia. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Dopa-responsive dystonia'
         </a>
         .)
        </p>
        <p>
         The hallmark of DRD is a clinically significant, sustained response to levodopa. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Paroxysmal dyskinesia with dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several rare genetic forms of dystonia are characterized by paroxysmal dyskinesia and discussed here briefly  (
         <a class="graphic graphic_table graphicRef59044" href="/z/d/graphic/59044.html" rel="external">
          table 5
         </a>
         ). They are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Paroxysmal dyskinesia with dystonia'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paroxysmal nonkinesigenic dyskinesia (PNKD) is characterized by spontaneous episodes of dystonia and/or choreoathetosis not triggered by exercise or activity. Alcohol, coffee, tea, fatigue, stress, or excitement may be precipitating factors. Episodes last minutes to hours and recur two or three times a month.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paroxysmal kinesigenic choreoathetosis, also known as paroxysmal kinesigenic dyskinesia, is characterized by episodic choreoathetosis and dystonia brought on by voluntary movement. The disorder is genetically heterogeneous.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paroxysmal exertion-induced dyskinesia is an autosomal dominant disorder with reduced penetrance that begins in childhood with dyskinesia and dystonia induced by prolonged exertion (eg, ≥15 minutes), fasting and stress. Associated features include absence and/or partial complex seizures.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H192849077">
         <span class="h3">
          Neurodegeneration with brain iron accumulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurodegeneration with brain iron accumulation (NBIA) represents a group of disorders that includes pantothenate kinase-associated neurodegeneration, infantile neuroaxonal dystrophy, fatty acid hydroxylase-associated neurodegeneration, aceruloplasminemia, neuroferritinopathy, and other conditions. Although dystonia is often a prominent feature, other hyperkinetic and bradykinetic movement disorders and neurologic deficits may also occur. (See
         <a class="medical medical_review" href="/z/d/html/6231.html" rel="external">
          "Bradykinetic movement disorders in children", section on 'Neurodegeneration with brain iron accumulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional causes of paroxysmal or fluctuating dystonia in children  (
         <a class="graphic graphic_table graphicRef51622" href="/z/d/graphic/51622.html" rel="external">
          table 3
         </a>
         ) include multiple sclerosis, thyrotoxicosis, metabolic disorders (eg, Hartnup disease), paroxysmal dystonia in sleep (hypnogenic dystonia), "infectious torticollis," and the GLUT1 deficiency syndrome [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H58621081">
         <span class="h2">
          Pseudodystonias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some conditions  (
         <a class="graphic graphic_table graphicRef141015" href="/z/d/graphic/141015.html" rel="external">
          table 6
         </a>
         ) may result in abnormal movements, postures, or spasms that mimic dystonia (ie, pseudodystonia), including gastroesophageal reflux (Sandifer syndrome). In addition, dystonia may be erroneously attributed to a postural deformity that results from common musculoskeletal or orthopedic problems such as congenital torticollis or scoliosis. (See
         <a class="medical medical_review" href="/z/d/html/6462.html" rel="external">
          "Acquired torticollis in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Treatment of dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate treatment of dystonia depends upon an accurate diagnosis [
         <a href="#rid23">
          23
         </a>
         ]. Patients with atypical features, such as impaired intellect, seizures, neuro-ophthalmologic abnormalities, ataxia, corticospinal tract signs, sensory deficits, severe speech disturbance, and unilateral distribution of the dystonia, are more likely to have an underlying disorder that can be treated, such as Wilson disease.
        </p>
        <p>
         The treatment of dystonia is reviewed here briefly and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pediatric patients with focal or generalized dystonia of unknown etiology, we recommend a trial of levodopa to confirm or exclude the diagnosis of dopa-responsive dystonia. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with multifocal or generalized isolated dystonia who do not respond to levodopa can be treated with other oral medications, botulinum toxin injections, or deep brain stimulation in refractory cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with debilitating generalized isolated dystonia that does not respond to a trial of levodopa, treatment with
         <a class="drug drug_pediatric" data-topicid="12863" href="/z/d/drug information/12863.html" rel="external">
          trihexyphenidyl
         </a>
         is suggested. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults", section on 'Anticholinergic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For debilitating multifocal or generalized isolated dystonia that does not respond to pharmacologic treatment, we suggest botulinum toxin injection of selected muscles. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults", section on 'Refractory disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with debilitating multifocal or generalized isolated dystonia who do not respond to pharmacologic therapy or botulinum toxin injections, we suggest bilateral deep brain stimulation of the internal globus pallidus. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults", section on 'Deep brain stimulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5579594">
         <span class="h3">
          Status dystonicus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Status dystonicus (also called dystonic storm) is a rare, life-threatening condition characterized by increasingly frequent or continuous severe generalized dystonic contractions that may be refractory to standard medical treatment [
         <a href="#rid15">
          15
         </a>
         ]. Status dystonicus can occur in children and adults as a result of progressive worsening in various types of dystonia, often in the setting of an identifiable trigger such as intercurrent illness or infection [
         <a href="#rid15">
          15,16,24,25
         </a>
         ]. Although data are limited by the small number of published cases (approximately 100) [
         <a href="#rid24">
          24
         </a>
         ], commonly reported complications include bulbar weakness, progressive impairment of respiratory function leading to respiratory failure, exhaustion, pain, and metabolic derangements including rhabdomyolysis and acute kidney injury [
         <a href="#rid15">
          15,24
         </a>
         ].
        </p>
        <p>
         Status dystonicus constitutes a neurologic emergency and requires urgent intervention. Management includes the following measures [
         <a href="#rid24">
          24,26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supportive care:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intensive care unit admission
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intravenous hydration
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antipyretics and cooling blankets
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pain control
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitoring for the development of rhabdomyolysis (eg, creatine kinase, urinalysis, and renal function)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sedation with intravenous
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         or intravenous
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Airway support including mechanical ventilation when necessary
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific measures to treat dystonia [
         <a href="#rid24">
          24-26
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial use of oral agents, often in combination:
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12863" href="/z/d/drug information/12863.html" rel="external">
          Trihexyphenidyl
         </a>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Benzodiazepines (unless
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         already being used)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          Tetrabenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">
          deutetrabenazine
         </a>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          Baclofen
         </a>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Gabapentin
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For chronic and/or refractory cases, consideration of invasive treatments:
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Botulinum toxin injection for focal and/or segmental dystonia
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intrathecal
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ]
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Deep brain stimulation of the globus pallidus interna [
         <a href="#rid28">
          28-33
         </a>
         ]
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pallidotomy [
         <a href="#rid34">
          34
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5579970">
         <span class="h3">
          Acute dystonic reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         An acute dystonic reaction, usually transient, is a recognized complication of the dopamine receptor-blocking drugs, such as the antipsychotics (eg,
         <a class="drug drug_pediatric" data-topicid="13347" href="/z/d/drug information/13347.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13150" href="/z/d/drug information/13150.html" rel="external">
          chlorpromazine
         </a>
         ) and antiemetics (eg, phenothiazines,
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         ) [
         <a href="#rid35">
          35-37
         </a>
         ]. Dystonic reactions also can occur with levodopa, anticonvulsants, antidepressants (eg, selective serotonin reuptake inhibitors), and ergots.
        </p>
        <p>
         Treatment of acute dystonia with antihistamine or anticholinergic medications is usually rapidly effective [
         <a href="#rid37">
          37,38
         </a>
         ]. Parenteral
         <a class="drug drug_pediatric" data-topicid="13236" href="/z/d/drug information/13236.html" rel="external">
          diphenhydramine
         </a>
         at 1 to 2 mg/kg per dose (maximum dose 50 mg) is used most frequently and typically results in resolution of an acute dystonic reaction within minutes. Intravenous administration is preferred over oral administration for initiation of treatment because patients may have difficulty swallowing. Parenteral administration is required for life-threatening dystonia with associated laryngospasm or stridor [
         <a href="#rid38">
          38
         </a>
         ]. Diphenhydramine may also be given intramuscularly but the onset of action is delayed compared with intravenous administration. Intravenous
         <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">
          diazepam
         </a>
         is also effective in the treatment of acute dystonic reaction [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Once the acute dystonic reaction is treated,
         <a class="drug drug_pediatric" data-topicid="13236" href="/z/d/drug information/13236.html" rel="external">
          diphenhydramine
         </a>
         is given orally at 1.25 mg/kg per dose every six hours for one to two days to prevent recurrence. In some cases, however, a single dose of oral diphenhydramine or
         <a class="drug drug_pediatric" data-topicid="12863" href="/z/d/drug information/12863.html" rel="external">
          trihexyphenidyl
         </a>
         suffices. The offending drug should be discontinued.
        </p>
        <p>
         Patients treated with dopamine receptor-blocking agents occasionally develop persistent tardive dystonia after the offending drug is stopped. If no spontaneous improvement occurs, they may respond to trials of muscle relaxants, anticholinergic drugs, or dopamine depleting agents such as
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">
          deutetrabenazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">
          valbenazine
         </a>
         [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          STEREOTYPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As defined by the Taskforce on Childhood Movement Disorders, "stereotypies are repetitive, simple movements that can be voluntarily suppressed" [
         <a href="#rid2">
          2
         </a>
         ]. Examples include repetitive chewing, rocking, twirling, or touching. These movements typically occur in children with infantile autism, intellectual disability, or other developmental disorders such as Rett syndrome  (
         <a class="graphic graphic_table graphicRef78875" href="/z/d/graphic/78875.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/627.html" rel="external">
          "Autism spectrum disorder in children and adolescents: Clinical features", section on 'Stereotyped behaviors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">
          "Rett syndrome: Genetics, clinical features, and diagnosis", section on 'Classification and major features'
         </a>
         .)
        </p>
        <p>
         In addition, stereotypies can occur in otherwise normal children. The clinical features and course of complex stereotypies of the upper extremity were described in a case series of 40 children and adolescents from a tertiary specialty clinic [
         <a href="#rid42">
          42
         </a>
         ]. The following features were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mean age was 7.9 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         90 percent had onset before 3 years of age
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         90 percent had occurrence at least daily, but were not reported to occur during sleep
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The typical duration of episodes ranged from &lt;10 seconds (30 percent) to &gt;60 seconds (30 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The movement involved flapping in 48 percent, shaking in 28 percent, clenching-stiffening-posturing in 38 percent, and ritual in 13 percent of patients
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The movement stopped when cued in all but one patient
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triggers included excitement, boredom, being focused or engrossed, and anxiety/stress
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         25 percent had comorbid attention deficit hyperactivity disorder
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         20 percent had comorbid learning disability
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         25 percent had a positive family history of stereotypies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical course involved resolution in 5 percent, improvement in 33 percent, no change in 50 percent, and worsening in 13 percent of patients
        </p>
        <p>
        </p>
        <p>
         In addition to autistic disorders, there are many other causes of stereotypies, such as tardive dyskinesia, probably the most common cause of stereotypy in adults [
         <a href="#rid43">
          43,44
         </a>
         ]. One of the most common stereotypies occurring in children and adults is leg stereotypy syndrome, which may occur in approximately 7 percent of otherwise normal individuals and in up to 17 percent of patients with other movement disorders [
         <a href="#rid45">
          45
         </a>
         ]. This condition is typically manifested by repetitive, continuous movement present almost exclusively in the legs while the individual is seated. It may also occur while standing, during which time it involves not only the legs but may be also manifested by swaying of the trunk. While some individuals describe these movements as soothing, there is no evidence that they are associated with or driven by anxiety or an irresistible urge to move, as is typically seen with akathisia or restless legs syndrome. The affected individual may not be even aware of the repetitive movement, but it may be quite annoying to those in close proximity. This leg stereotypy syndrome is clearly separate from restless legs syndrome, which is often very troublesome to the patient and does not have diurnal variation.
        </p>
        <p>
         Intellectual impairment is another condition frequently associated with stereotypies. In individuals with intellectual impairment, such as Lesch-Nyhan syndrome, stereotypies may be associated with self-injurious behavior. Supersensitivity of D1 receptors, possibly in response to abnormal arborization of dopamine neurons in the striatum, has been postulated as a possible mechanism of self-injurious behavior in Lesch-Nyhan syndrome. Dopamine receptor blockers or dopamine depleters, such as
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         , have been noted to ameliorate stereotypies and self-injurious behaviors [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Rett syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rett syndrome is an example of a disorder characterized by marked stereotypies [
         <a href="#rid47">
          47
         </a>
         ]. This condition is one of the most common causes of intellectual disability in females. Most cases are caused by variants in the gene for methyl-CpG-binding protein 2 (
         <em>
          MeCP2
         </em>
         ).
        </p>
        <p>
         Rett syndrome typically presents at 6 to 18 months of age in girls with previously normal growth and development. Affected patients regress in their verbal and motor skills, lose purposeful use of their hands, and have jerky ataxia and typical stereotyped movements of the hands resembling hand washing and kneading. Other symptoms include breath-holding spells, hyperventilation, loss of facial expression, poor eye contact, bruxism, dystonia, occasional seizures, apparent insensitivity to pain, and a variety of self-injurious and aggressive behaviors.
        </p>
        <p>
         The clinical features, diagnosis and management of Rett syndrome are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">
          "Rett syndrome: Genetics, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          CHOREA, ATHETOSIS, AND BALLISMUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children can be affected by many acquired and hereditary types of chorea and related movement disorders  (
         <a class="graphic graphic_table graphicRef79166" href="/z/d/graphic/79166.html" rel="external">
          table 8
         </a>
         ). The following definitions from the Taskforce on Childhood Movement Disorders apply [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chorea is an ongoing random-appearing sequence of one or more discrete involuntary movements or movement fragments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Athetosis is defined as "a slow, continuous, involuntary writhing movement that prevents maintenance of a stable posture" and thus represents a form of slow chorea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ballism (ballismus) is defined "as chorea that affects proximal joints such as shoulder or hip," leading to "large amplitude movements of the limbs, sometimes with a flinging or flailing quality"; it is usually unilateral (hemiballismus) and often results from a lesion in the contralateral subthalamic nucleus and adjacent structures.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Physiologic chorea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Almost all normal infants make movements that resemble chorea, but this physiologic chorea resolves by eight months of age. Children with attention deficit disorder and hyperactivity may have distal chorea (chorea minima).
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Cerebral palsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebral palsy is a common cause of chorea in children. Chorea or athetosis (choreoathetosis) is the predominant motor disturbance in approximately one-third of cases but occurs to a variable degree in almost all patients [
         <a href="#rid48">
          48
         </a>
         ]. In one series, choreoathetosis was apparent in one-half of patients during the first year and developed in the remainder during the next four to five years, after which it remained static. Most patients with athetoid cerebral palsy were born prematurely (60 percent) or had a perinatal history of jaundice and/or asphyxia (82 percent). Dystonia also is common, occurring in up to 70 percent of cases.
        </p>
        <p>
         Several patients have been reported with choreoathetosis and dystonia that is delayed in onset and progressive, in contrast to the nonprogressive neurologic impairment in cerebral palsy. The mechanism is attributed to sprouting and denervation supersensitivity of receptors in the basal ganglia.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Sydenham chorea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sydenham chorea is one of the major clinical manifestations of acute rheumatic fever and the most common form of acquired chorea in childhood. The initial presentation typically occurs in patients between 5 and 13 years of age. This disorder is discussed in detail elsewhere and will be reviewed briefly here. (See
         <a class="medical medical_review" href="/z/d/html/6228.html" rel="external">
          "Sydenham chorea"
         </a>
         .)
        </p>
        <p>
         Chorea usually develops one to eight months after the inciting infection, in contrast to carditis and arthritis which most often present within 21 days [
         <a href="#rid49">
          49
         </a>
         ]. The onset is usually insidious but may be abrupt.
        </p>
        <p>
         The chorea typically begins with distal movements of the hands, but generalized jerking of the face and feet emerges as the chorea becomes more active. The movements are rapid, irregular, and nonstereotyped jerks that are continuous while the patient is awake but improve with sleep. The chorea is usually generalized but may be more prominent on one side; approximately 20 percent of patients have hemichorea (ie, unilateral chorea). Emotional changes, such as easy crying or inappropriate laughing, may precede the development of chorea. In some cases, regression in school performance is the initial concern.
        </p>
        <p>
         The diagnosis of Sydenham chorea is made clinically as no specific laboratory test exists. Although the neuropathology of Sydenham chorea is not well studied, vasculitis involving the basal ganglia, cortex, and cerebellum has been identified in the brains of some affected patients [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Sydenham chorea typically improves gradually, with a mean duration of 12 to 15 weeks. Treatment includes antibiotic therapy with penicillin for at least 10 days followed by antibiotic prophylaxis. Specific treatment for the chorea may be warranted when significant impairment of motor function and the possibility of self-injury are present. Treatments reported to be effective include
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproic acid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">
          phenobarbital
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13347" href="/z/d/drug information/13347.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13017" href="/z/d/drug information/13017.html" rel="external">
          pimozide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13150" href="/z/d/drug information/13150.html" rel="external">
          chlorpromazine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         . Corticosteroids may shorten the course of Sydenham chorea. (See
         <a class="medical medical_review" href="/z/d/html/6228.html" rel="external">
          "Sydenham chorea", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Post-pump chorea
         </span>
         <span class="headingEndMark">
          —
         </span>
         A dyskinetic movement disorder may complicate cardiac surgery in a small number of children with congenital heart disease. The estimated frequency of this complication is 10 percent (0.6 to 18 percent) per procedure, but the incidence appears to be decreasing over time, presumably as a result of changing operative techniques [
         <a href="#rid51">
          51-53
         </a>
         ].
        </p>
        <p>
         The complication has been described in children ages six weeks to 52 months [
         <a href="#rid51">
          51,54
         </a>
         ]. Risk factors include more time on pump, deeper hypothermia (&lt;36 degrees), and circulatory arrest [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Symptoms begin three to twelve days postoperatively [
         <a href="#rid51">
          51,55
         </a>
         ]. The dyskinesia is usually in the form of choreoathetosis and mainly involves the mouth, tongue and face [
         <a href="#rid55">
          55
         </a>
         ]. More severely affected children have involvement of extremities and trunk. Neuroimaging studies and electroencephalogram (EEG) are normal [
         <a href="#rid51">
          51,55
         </a>
         ].
        </p>
        <p>
         The underlying etiology is not understood. In two patients, neuropathologic findings included neuronal loss, reactive astrocytosis, and degeneration of myelinated fibers in the globus pallidus, primarily the outer segment [
         <a href="#rid56">
          56
         </a>
         ]. Locations typically affected by hypoxic ischemic insult were spared. In some milder and transient cases, certain medications (eg,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13112" href="/z/d/drug information/13112.html" rel="external">
          captopril
         </a>
         ) have been implicated [
         <a href="#rid57">
          57-59
         </a>
         ].
        </p>
        <p>
         The movements remit in some children over several weeks; others, particularly those who are more severely affected, have persistent chorea [
         <a href="#rid51">
          51
         </a>
         ]. Associated neurological deficits are common and range from mild learning deficits to hypotonia and obtundation [
         <a href="#rid51">
          51
         </a>
         ]. Severely affected children may die. In one series, 1 of 8 died [
         <a href="#rid51">
          51
         </a>
         ]; in another, 3 of 36 died [
         <a href="#rid54">
          54
         </a>
         ]. Abnormal motor, cognitive, and behavioral development is the rule among children followed over several years [
         <a href="#rid51">
          51,54
         </a>
         ]. Older children and those most severely affected at onset appear to be a higher risk for serious and more persistent deficits [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Other acquired causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kernicterus is a neurologic condition that may occur when serum total bilirubin concentrations in the perinatal period are excessive [
         <a href="#rid60">
          60
         </a>
         ]. In the chronic phase, the disorder is characterized by choreoathetosis, tremor, dystonia, rigidity, dysarthria, sensorineural hearing loss, and limitation of upward gaze. Affected infants may have increased signal intensity in the basal ganglia in T2-weighted magnetic resonance images because of deposition of bilirubin [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Chronic bilirubin encephalopathy (kernicterus)'
         </a>
         .)
        </p>
        <p>
         Some infants with severe bronchopulmonary dysplasia develop a movement disorder similar to chorea. In one report describing 10 infants, the condition developed at approximately the third postnatal month and involved the limbs, neck, trunk, and oral-buccal-lingual structures [
         <a href="#rid62">
          62
         </a>
         ]. The abnormalities completely or partially resolved in the seven surviving infants. A neuropathologic study of one infant showed neuronal loss with astrocytosis in the caudate, putamen, globus pallidus, and thalamus. (See
         <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Hereditary chorea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Huntington disease is one of the most frequent causes of hereditary chorea in children. (See
         <a class="medical medical_review" href="/z/d/html/6231.html" rel="external">
          "Bradykinetic movement disorders in children", section on 'Juvenile Huntington disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Childhood-onset hereditary chorea
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a growing list of genetically defined childhood-onset choreas. NK2 homeobox 1 (
         <em>
          NKX2-1)
         </em>
         -related chorea is an autosomal dominant disorder that presents during infancy or childhood. Previously referred to as "benign hereditary chorea" (BHC), this term is no longer appropriate as this form of chorea can be quite troublesome and even disabling. Nearly all reported patients are heterozygous for pathogenic variants in the
         <em>
          NKX2-1
         </em>
         gene (also known as the
         <em>
          TITF1
         </em>
         gene) on chromosome 14q13 [
         <a href="#rid63">
          63,64
         </a>
         ]. Variants in the
         <em>
          ADCY5
         </em>
         gene have been identified in rare individuals with an
         <em>
          NKX2-1
         </em>
         phenotype who were negative for
         <em>
          NKX2-1
         </em>
         variants [
         <a href="#rid65">
          65
         </a>
         ]; not all cases were "benign," as some patients exhibited dystonia, hypotonia, and other motor disorders that can significantly impair quality of life (see
         <a class="local">
          'ADCY5-related dyskinesia'
         </a>
         below). Patients thought to have BHC require thorough investigation and follow-up because some are diagnosed subsequently with other conditions [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         As observed in one of the largest reports, which analyzed 28 patients and reviewed the literature, the typical features of
         <em>
          NKX2-1
         </em>
         chorea include onset in infancy with marked hypotonia followed by generalized chorea [
         <a href="#rid67">
          67
         </a>
         ]. Most children are delayed in motor and walking milestones. Associated neurologic features may include myoclonus, upper limb dystonia, and motor and vocal tics. The chorea is nonprogressive and often lessens over time or resolves by early adulthood. However, patients who have myoclonus and chorea early in the course of the disease sometimes develop worsening myoclonus, which becomes the major source of disability as the chorea improves [
         <a href="#rid68">
          68
         </a>
         ]. Cognitive and behavioral disturbances, most often learning difficulties, and less often attention deficit hyperactivity disorder or intellectual disability, are common [
         <a href="#rid67">
          67
         </a>
         ]. Other comorbid features reported in some affected individuals include growth hormone deficiency, pes cavus, kyphosis, duplex kidney anomaly, and obsessive-compulsive disorder [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Frequent systemic manifestations of
         <em>
          NKX2-1
         </em>
         chorea are thyroid disease, with hypothyroidism or thyroid gland abnormalities on ultrasound, and pulmonary disease, manifesting as neonatal respiratory distress or recurrent pulmonary infections [
         <a href="#rid67">
          67
         </a>
         ]. Thus, the phenotype of
         <em>
          NKX2-1
         </em>
         chorea includes the syndrome of choreoathetosis, hypothyroidism, and neonatal respiratory distress (also known as brain-thyroid-lung syndrome), which is also caused by variants in the
         <em>
          NKX2-1
         </em>
         gene [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p>
         The neurologic manifestations of
         <em>
          NKX2-1
         </em>
         chorea may be related to impaired cerebral glucose metabolism in the caudate nucleus, as demonstrated by positron emission tomography (PET) with 18F-2-fluorodeoxyglucose [
         <a href="#rid72">
          72
         </a>
         ]. However, this finding has not been observed in all cases [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Although there is no established therapy for
         <em>
          NKX2-1
         </em>
         chorea, one study reported that treatment with
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         (using a dose of 0.5 mg/kg per day for children and 37.5 mg per day for adults) was associated with rapid and lasting improvement in chorea for five of eight patients [
         <a href="#rid67">
          67
         </a>
         ]. In another report, treatment with levodopa (dose range 7 to 20 mg/kg per day) was associated with sustained improvement of gait and chorea for two patients [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1974243265">
         <span class="h3">
          ADCY5-related dyskinesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          ADCY5
         </em>
         -related dyskinesia has a broad phenotypic spectrum with various manifestations including fluctuating dyskinesia, dystonia, chorea, myoclonus, axial hypotonia, painful spasms associated with falls, and sleep disturbances [
         <a href="#rid75">
          75-78
         </a>
         ]. Onset is in childhood, often in infancy. The frequency and severity of abnormal movements can be highly variable. Cognitive impairment is mild or absent, and brain magnetic resonance imaging (MRI) is unrevealing. The disorder is often disabling [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
         There is one report of several patients who experienced dramatic, sustained improvement in
         <em>
          ADCY5
         </em>
         -related dyskinesia with caffeine administered by drinking coffee [
         <a href="#rid79">
          79
         </a>
         ]. Very limited data suggest that some patients have mild improvement with
         <a class="drug drug_pediatric" data-topicid="13170" href="/z/d/drug information/13170.html" rel="external">
          clonazepam
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="83321" href="/z/d/drug information/83321.html" rel="external">
          clobazam
         </a>
         [
         <a href="#rid78">
          78
         </a>
         ]. In one report, three patients (two children and one adult) with
         <em>
          ADCY5
         </em>
         -related movement disorders who failed medication treatment trials had variable and partial improvement in hyperkinetic manifestations with deep brain stimulation [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Lesch-Nyhan syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lesch-Nyhan syndrome is a complex motor-behavioral condition that is inherited as an X-linked recessive trait. The disorder results from pathogenic variants in the gene coding for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT), leading to deficient enzyme activity. This defect results in an often marked increase in production of uric acid and hyperuricemia.
        </p>
        <p>
         More than 2000 variants of the
         <em>
          HPRT
         </em>
         gene have been reported, and the wide spectrum of neurologic symptoms (with some patients being asymptomatic) and severity of the disease have been associated with the degree of enzyme deficiency [
         <a href="#rid81">
          81-83
         </a>
         ].
        </p>
        <p>
         Affected boys have delayed developmental milestones, intellectual disability, and extrapyramidal and pyramidal motor symptoms; they also develop self-mutilating behavior.
        </p>
        <p>
         While earlier literature emphasized choreoathetosis and spasticity as typical features of the motor disorder associated with Lesch-Nyhan syndrome, dystonia may be more common. This observation comes from a prospective observational study of a series of 44 patients with complete HPRT deficiency [
         <a href="#rid84">
          84
         </a>
         ]. The study found a characteristic evolution of motor involvement, which began at three to six months of age with hypotonia, with or without delayed acquisition of motor skills. Involuntary movements, predominantly dystonia, developed between six and 24 months. Thereafter, the clinical course is relatively static and characterized by severe action dystonia with baseline hypotonia. Extrapyramidal symptoms such as choreoathetosis or ballismus may occur, but are less prominent than dystonia.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          ESSENTIAL TREMOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         As defined by the Taskforce on Childhood Movement Disorders, "tremor is a rhythmic back-and-forth or oscillating involuntary movement about a joint axis" [
         <a href="#rid2">
          2
         </a>
         ]. Back-and-forth is further stipulated to mean "a relatively symmetric velocity in both directions about a midpoint of the movement, and the velocity or oscillation may appear sinusoidal." Although of relatively constant frequency, the amplitude may be variable. Tremor is caused by either alternating or synchronous contractions of antagonistic muscles [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         By definition, tremor should be the only neurologic manifestation of essential tremor (ET). ET usually is a benign condition. However, it may progress to a disabling movement disorder that interferes with feeding, speaking, writing, and other activities of daily living.
        </p>
        <p>
         The cause of ET is uncertain. One form is inherited in an autosomal dominant manner. At least two loci have been identified: one on chromosome 3q13 and one on chromosome 2p22 [
         <a href="#rid86">
          86,87
         </a>
         ]. Although no neurotransmitter abnormalities have been demonstrated in ET, physiologic studies have demonstrated dysfunction of the cerebellar system.
        </p>
        <p>
         ET is the most common cause of an oscillatory involuntary movement disorder in childhood  (
         <a class="graphic graphic_table graphicRef69074" href="/z/d/graphic/69074.html" rel="external">
          table 9
         </a>
         ). ET may start at any age, including infancy. The clinical features of childhood-onset ET were described in a case series of 39 patients who were evaluated in a movement disorders clinic [
         <a href="#rid88">
          88
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mean age of onset was 8.8 years (range 1 to 16 years), with a mean age of evaluation of 20.3 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The majority of patients were boys (74 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         46 percent of patients had some neurologic comorbidity, including dystonia, which was present in 28 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         80 percent of patients reported at least one relative with tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exacerbating factors included stress, anxiety, physical activity, and caffeine
        </p>
        <p>
        </p>
        <p>
         Two forms of hereditary ET that may begin in infancy are hereditary chin tremor and shuddering attacks.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Hereditary chin tremor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary chin tremor (also called hereditary geniospasm) consists of rhythmic contractions of the chin that occur at a frequency of 3/sec. This condition is inherited in an autosomal dominant pattern, with one locus on chromosome 9q13, and often is associated with deafness [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Shuddering attacks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Shuddering attacks begin during infancy or early childhood. Affected children have bursts of rapid trembling of the entire body, occasionally associated with head turning, involuntary sniffing, and throat clearing [
         <a href="#rid90">
          90,91
         </a>
         ]. They usually fall to the floor if they have been standing. More than 100 attacks per day may occur; on the other hand, patients may be free of symptoms for as long as two weeks. The episodes tend to decrease in frequency or disappear over time [
         <a href="#rid91">
          91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6210.html" rel="external">
          "Nonepileptic paroxysmal disorders in infancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Other variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another form of ET seen in children is an action-postural tremor that consists of slower and faster components. The slower tremor (approximately 6.5 Hz) typically involves the head and neck, whereas the more rapid tremor (8 to 12 Hz) usually involves the hands.
        </p>
        <p>
         Other oscillatory involuntary movements occasionally are seen in infants and children. They include "head nodding," which is often associated with congenital nystagmus, including spasmus nutans, and the "bobble-head doll syndrome," which occurs with diencephalic lesions, including third-ventricle cysts or tumors, craniopharyngioma, hydrocephalus, and hypothalamic lesions.
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy for ET is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4898.html" rel="external">
          "Essential tremor: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4901.html" rel="external">
          "Surgical treatment of essential tremor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          MYOCLONUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As defined by the Taskforce on Childhood Movement Disorders, "Myoclonus is a sequence of repeated, often nonrhythmic, brief shock-like jerks due to sudden involuntary contraction or relaxation of one or more muscles" [
         <a href="#rid2">
          2
         </a>
         ]. Myoclonus is not coordinated or suppressible and is often activated by volitional movement. Myoclonus can be physiologic or pathologic and can occur as an isolated disorder or associated with seizures or other conditions  (
         <a class="graphic graphic_table graphicRef78331" href="/z/d/graphic/78331.html" rel="external">
          table 10
         </a>
         ). One of the main considerations in the differential diagnosis of myoclonus is myoclonus-dystonia (DYT11) caused by variants of the
         <em>
          SGCE
         </em>
         gene, but there are a growing number of novel gene variants associated with the myoclonus-dystonia syndrome [
         <a href="#rid92">
          92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4885.html" rel="external">
          "Classification and evaluation of myoclonus", section on 'Myoclonus-dystonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Benign neonatal sleep myoclonus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benign neonatal sleep myoclonus occurs in the first month after birth. It usually occurs in the early stages of sleep and is stimulus-sensitive. It should be differentiated from neonatal seizures and infantile spasms. (See
         <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">
          "Clinical features, evaluation, and diagnosis of neonatal seizures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6145.html" rel="external">
          "Infantile epileptic spasms syndrome: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h2">
          Essential myoclonus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Essential myoclonus has no associated neurologic deficit, although it may be associated with ET. The disorder is inherited in an autosomal dominant pattern or may occur sporadically. It typically begins before the patient reaches age 20 years [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h2">
          Cortical myoclonus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cortical myoclonus consists of continuous, repetitive, focal jerking that sometimes is associated with characteristic EEG changes. The myoclonus may be triggered by external stimuli or evoked by muscle stretch reflex.
        </p>
        <p>
         The underlying mechanism of cortical myoclonus is thought to be a hyperexcitable sensorimotor cortex. In cortical reflex myoclonus, quick, passive movement of a distal phalanx elicits the myoclonic movement. This movement is preceded by a specific EEG event and enhanced amplitude of the somatosensory evoked potential. In cortical action myoclonus, myoclonus is elicited by active movement which may have an EEG correlate.
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h2">
          Epilepsia partialis continua
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epilepsia partialis continua (partial status epilepticus) may be associated with myoclonus. Common causes include cortical stroke and Rasmussen encephalitis, which results from a focal cortical lesion or inflammation possibly induced by viral infection.
        </p>
        <p>
         Reticular reflex myoclonus is thought to result from a hyperexcitable brainstem reticular formation, particularly the nucleus reticularis gigantocellularis.
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h2">
          Unverricht-Lundborg disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unverricht-Lundborg disease (ULD or EPM1; MIM #254800), also known as "Mediterranean" or "Baltic" myoclonus, is one form of progressive myoclonus epilepsy (PME), a condition that consists of myoclonus, seizures, and a progressive clinical course [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         In the EPM1 form, stimulus-sensitive myoclonus usually begins between ages 6 and 15 years [
         <a href="#rid94">
          94
         </a>
         ]. Affected patients develop dysarthria, ataxia, intention tremor, and mild intellectual decline; many become bedridden within five years after onset of symptoms. In approximately 10 percent of cases, the disease follows a milder course, and some patients may remain mildly symptomatic and independent for decades [
         <a href="#rid95">
          95
         </a>
         ]. Epileptiform EEG findings may precede symptoms by up to three years. The diagnosis of EPM1 can be confirmed by genetic studies [
         <a href="#rid94">
          94
         </a>
         ]. An earlier age of onset and longer disease duration are associated with more severe disease manifestations, including disabling myoclonus [
         <a href="#rid95">
          95,96
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          Valproate
         </a>
         is often effective for EPM1, reducing myoclonus and seizure-frequency [
         <a href="#rid94">
          94,97
         </a>
         ]. By contrast,
         <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">
          phenytoin
         </a>
         has been associated with exacerbations. A French case series suggests that, with improved treatment, the course is not necessarily dire and stabilizes after five to ten years [
         <a href="#rid97">
          97
         </a>
         ]. Among 20 patients with ULD who were followed over 25 years, only three were severely handicapped, and six led fully independent lives. In a Finnish population-based study that included 135 patients with EPM1, the median age at death was 54 years [
         <a href="#rid95">
          95
         </a>
         ]. Comprehensive rehabilitative management is also helpful and can extend life [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         EPM1 is inherited in an autosomal recessive pattern. The responsible cystatin B (
         <em>
          CSTB
         </em>
         ) gene is localized to 21q22 and encodes cystatin B, a cysteine protease inhibitor [
         <a href="#rid98">
          98-101
         </a>
         ]. Several different variants have been identified in the
         <em>
          CSTB
         </em>
         gene in patients with EPM1, but the most common is an unstable expansion of a dodecamer minisatellite repeat unit in the promoter region [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         A novel form of ULD that maps to chromosome 12 has been described in an Arab family [
         <a href="#rid102">
          102
         </a>
         ]. The locus on chromosome 12 (designated EPM1B) does not have genes known to be related to cystatin B or other forms of PME. The clinical phenotype of EPM1B is similar to EPM1, but appears to be distinguished by an earlier age of onset.
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h2">
          Lafora body disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lafora body disease (MIM #254780) is another form of progressive myoclonus epilepsy (PME) that is characterized by progressive and intractable myoclonic and photoconvulsive seizures, dementia, apraxia, and cortical blindness. Age of onset is usually between ages 11 and 18 years. Total disability typically occurs within 10 years, though some patients have a milder, more slowly progressive form of the disease [
         <a href="#rid103">
          103
         </a>
         ]. Biopsy of the skin (especially in the axillary region) [
         <a href="#rid104">
          104
         </a>
         ], liver, muscle, or brain reveals pathognomonic polyglucosan inclusions (Lafora bodies) that appear positive on periodic acid-Schiff staining.
        </p>
        <p>
         The mode of inheritance is autosomal recessive. Lafora body disease is caused by variants in the
         <em>
          EPM2A
         </em>
         gene and the
         <em>
          NHLRC1
         </em>
         gene (previously known as the
         <em>
          EPM2B
         </em>
         gene) [
         <a href="#rid105">
          105-108
         </a>
         ], and an early-onset form of Lafora body disease may be caused by a variant in the
         <em>
          PRDM8
         </em>
         gene [
         <a href="#rid109">
          109,110
         </a>
         ]. The
         <em>
          EPM2A
         </em>
         gene codes for the protein laforin [
         <a href="#rid105">
          105,106
         </a>
         ], and the
         <em>
          NHLRC1
         </em>
         gene codes for the protein malin [
         <a href="#rid107">
          107
         </a>
         ]. Laforin has a starch binding domain [
         <a href="#rid106">
          106
         </a>
         ], while malin binds laforin [
         <a href="#rid109">
          109
         </a>
         ], suggesting that both proteins interact in a cellular pathway that protects against polyglucosan accumulation and epilepsy [
         <a href="#rid107">
          107,109
         </a>
         ]. The
         <em>
          PRDM8
         </em>
         gene codes for a protein that interacts with and translocates laforin and malin to the nucleus; the mutated form may result in a deficiency of laforin and malin in the cytoplasm.
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h2">
          Hyperekplexia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperekplexia, or "human startle disease," is a rare neurologic disorder characterized by generalized stiffness beginning in infancy [
         <a href="#rid111">
          111,112
         </a>
         ]. Affected patients develop exaggerated myoclonic startle reactions and a short period of generalized stiffness following the startle that may result in falling.
        </p>
        <p>
         Both hereditary and sporadic hyperekplexia are genetically heterogeneous. The most common hereditary form (MIM 149400) is caused by variants in the glycine receptor alpha 1 (
         <em>
          GLRA1
         </em>
         ) gene on chromosome 5, which lead to decreased inhibitory glycine signaling and hyperexcitability in motor nerves [
         <a href="#rid113">
          113,114
         </a>
         ]. Both autosomal dominant and recessive forms have been described, and the phenotypic spectrum includes milder as well as later-onset cases [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         Other hyperekplexia genes include glycine receptor beta (
         <em>
          GLRB
         </em>
         ) [
         <a href="#rid115">
          115
         </a>
         ], ATPase family AAA domain containing 1 (
         <em>
          ATAD1
         </em>
         ) [
         <a href="#rid116">
          116
         </a>
         ], and solute carrier family 6 member 5 (
         <em>
          SLC6A5
         </em>
         ), which encodes a presynaptic glycine transporter [
         <a href="#rid117">
          117
         </a>
         ]. The
         <em>
          SLC6A5
         </em>
         variants are predominately associated with recessive hyperekplexia; symptoms include life-threatening neonatal apnea and breath-holding spells [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
         Hyperekplexia with an excessive startle response may also be a feature of a number of severe neurometabolic and neurodevelopmental disorders such as Tay-Sachs disease and some early infantile epileptic encephalopathies.
        </p>
        <p>
         The clinical features and management of hyperekplexia in infants are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6210.html" rel="external">
          "Nonepileptic paroxysmal disorders in infancy", section on 'Hyperekplexia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other types of symptomatic (secondary) myoclonus include the following  (
         <a class="graphic graphic_table graphicRef78331" href="/z/d/graphic/78331.html" rel="external">
          table 10
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ramsay Hunt syndrome is a group of heterogeneous disorders characterized by a combination of progressive myoclonus and cerebellar ataxia. (See
         <a class="medical medical_review" href="/z/d/html/4884.html" rel="external">
          "Symptomatic (secondary) myoclonus", section on 'Progressive myoclonic epilepsy and progressive myoclonic ataxia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subacute sclerosing panencephalitis after viral encephalitis (eg, measles) may present with progressive dementia and slow myoclonus that occurs at a rate of approximately one per second and is associated with periodic complexes on EEG.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opsoclonus-myoclonus syndrome or "dancing eyes-dancing feet" syndrome may occur in young children after a febrile viral illness or as a paraneoplastic syndrome associated with neuroblastoma. This disorder often improves with steroid therapy. The pathogenesis is thought to be immune mediated, but the precise mechanism remains unclear. One study found that B and T cell markers correlated with neurologic severity [
         <a href="#rid118">
          118
         </a>
         ], and another found evidence of autoantibody reactivity to a neuronal surface antigen [
         <a href="#rid119">
          119
         </a>
         ], but no single antibody has been consistently identified in children with this disorder [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5204.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of neuroblastoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small myoclonic jerks (minipolymyoclonus) may occur in children with chronic spinal muscular atrophy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H40">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of myoclonus is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4888.html" rel="external">
          "Treatment of myoclonus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23737028">
         <span class="h1">
          MOVEMENT DISORDERS WITH ANTI-NMDAR ENCEPHALITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a neuropsychiatric disorder characterized by behavioral and psychiatric manifestations, followed by a subacute onset of a variety of movement disorders, including chorea, stereotypies particularly affecting the orofacial area, dystonia, slow tremor (myorhythmia), blepharospasm, opisthotonus, athetosis, and ataxia [
         <a href="#rid120">
          120-123
         </a>
         ]. Atypical presentations have also been described. In one report, three children with positive anti-NMDAR antibodies presented with different movement disorders (hemichorea, chorea and myoclonus) in the absence of encephalopathy [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         Anti-NMDAR encephalitis is often associated with ovarian teratoma and other benign tumors. Brain MRI is abnormal in approximately one-half of the patients, but cerebrospinal fluid pleocytosis is found in most cases. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-NMDA receptor encephalitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1096055602">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121121.html" rel="external">
          "Society guideline links: Tourette syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/140090.html" rel="external">
          "Society guideline links: Huntington disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7767083">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83332.html" rel="external">
          "Patient education: Dystonia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22512652">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tics
         </strong>
         – Tics are repeated, individually recognizable, intermittent movements or movement fragments that are almost always briefly suppressible and are usually associated with awareness of an urge to perform the movement  (
         <a class="graphic graphic_table graphicRef61505" href="/z/d/graphic/61505.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Tic disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple motor and vocal (phonic) tics are the hallmark of Tourette syndrome, a common movement and neurobehavioral disorder in children. (See
         <a class="medical medical_review" href="/z/d/html/6221.html" rel="external">
          "Tourette syndrome: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dystonia
         </strong>
         – Dystonia is characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both; dystonic movements are typically patterned, twisting, and may be tremulous. Dystonia is often initiated or worsened by voluntary action and associated with overflow muscle activation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dystonia is classified based upon clinical characteristics and etiology  (
         <a class="graphic graphic_table graphicRef59278" href="/z/d/graphic/59278.html" rel="external">
          table 2
         </a>
         ). Cerebral palsy is probably the most common cause of acquired dystonia seen in children  (
         <a class="graphic graphic_table graphicRef51622" href="/z/d/graphic/51622.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Dystonia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stereotypies
         </strong>
         – Stereotypies are repetitive, simple movements that can be voluntarily suppressed. Examples include repetitive chewing, rocking, twirling, or touching movements. These typically occur in children with infantile autism, intellectual disability, or other developmental disorders such as Rett syndrome  (
         <a class="graphic graphic_table graphicRef78875" href="/z/d/graphic/78875.html" rel="external">
          table 7
         </a>
         ). Stereotypies can also occur in otherwise healthy children. (See
         <a class="local">
          'Stereotypies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">
          "Rett syndrome: Genetics, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chorea and related movements
         </strong>
         – Children can be affected by many acquired and hereditary types of chorea and related movement disorders  (
         <a class="graphic graphic_table graphicRef79166" href="/z/d/graphic/79166.html" rel="external">
          table 8
         </a>
         ). Common causes of acquired chorea in children include cerebral palsy, Sydenham chorea, and post-pump chorea. A variety of rare hereditary disorders cause chorea, including but not limited to juvenile Huntington disease. (See
         <a class="local">
          'Chorea, athetosis, and ballismus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tremor
         </strong>
         – Tremor is a rhythmic back-and-forth or oscillating involuntary movement about a joint axis and occurs at a relatively symmetric velocity in both directions about a midpoint of the movement  (
         <a class="graphic graphic_table graphicRef69074" href="/z/d/graphic/69074.html" rel="external">
          table 9
         </a>
         ). Essential tremor (ET) is the most common movement disorder causing involuntary tremor in children. Two forms of hereditary ET that can begin in infancy are hereditary chin tremor and shuddering attacks. (See
         <a class="local">
          'Essential tremor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myoclonus
         </strong>
         – Myoclonus is a sequence of repeated, often nonrhythmic, brief shock-like jerks due to sudden involuntary contraction or relaxation of one or more muscles. Myoclonus is not coordinated or suppressible and is often activated by volitional movement. Myoclonus can be physiologic or pathologic and can occur as an isolated disorder or associated with seizures or other conditions  (
         <a class="graphic graphic_table graphicRef78331" href="/z/d/graphic/78331.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="local">
          'Myoclonus'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Jankovic J, Hallet M, Okun M, et al. Principles and Practice of Movement Disorders, 3rd ed, Elsevier, 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Self-injurious behavior in Tourette syndrome. J Neurol 2022; 269:2453.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol 2012; 47:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black KJ, Black ER, Greene DJ, Schlaggar BL. Provisional Tic Disorder: What to tell parents when their child first starts ticcing. F1000Res 2016; 5:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim S, Greene DJ, Bihun EC, et al. Provisional Tic Disorder is not so transient. Sci Rep 2019; 9:3951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pringsheim T, Ganos C, McGuire JF, et al. Rapid Onset Functional Tic-Like Behaviors in Young Females During the COVID-19 Pandemic. Mov Disord 2021; 36:2707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claudio-Campos K, Stevens D, Koo SW, et al. Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome? Mov Disord 2021; 36:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord 2013; 28:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Egmond ME, Kuiper A, Eggink H, et al. Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry 2015; 86:774.
          </a>
         </li>
         <li class="breakAll">
          Singer HS, Mink JW, Gilbert DL, Jankovic J. Movement Disorders in Childhood, 3rd ed, Butterworth-Heinemann (Elsevier), Philadelphia 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balint B, Mencacci NE, Valente EM, et al. Dystonia. Nat Rev Dis Primers 2018; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenkranz K, Williamon A, Butler K, et al. Pathophysiological differences between musician's dystonia and writer's cramp. Brain 2005; 128:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain 1998; 121 ( Pt 2):243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opal P, Tintner R, Jankovic J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord 2002; 17:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain neurotransmitters in dystonia. N Engl J Med 1987; 316:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998; 44:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conte A, Rocchi L, Latorre A, et al. Ten-Year Reflections on the Neurophysiological Abnormalities of Focal Dystonias in Humans. Mov Disord 2019; 34:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry 2002; 72:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange LM, Gonzalez-Latapi P, Rajalingam R, et al. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. Mov Disord 2022; 37:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang H, Wang D, Engelstad K, et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol 2011; 70:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics 2014; 11:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen NM, Lin JP, Lynch T, King MD. Status dystonicus: a practice guide. Dev Med Child Neurol 2014; 56:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini AG, Hassan I, Sharma K, et al. Status Dystonicus in Children: A Cross-Sectional Study and Review of Literature. J Child Neurol 2022; 37:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Medical treatment of dystonia. Mov Disord 2013; 28:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goswami JN, Roy S, Patnaik SK. Pediatric Dystonic Storm: A Hospital-Based Study. Neurol Clin Pract 2021; 11:e645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandas F, Fernandez-Carballal C, Guzman-de-Villoria J, Ampuero I. Treatment of a dystonic storm with pallidal stimulation in a patient with PANK2 mutation. Mov Disord 2011; 26:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jech R, Bares M, Urgosík D, et al. Deep brain stimulation in acute management of status dystonicus. Mov Disord 2009; 24:2291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apetauerova D, Schirmer CM, Shils JL, et al. Successful bilateral deep brain stimulation of the globus pallidus internus for persistent status dystonicus and generalized chorea. J Neurosurg 2010; 113:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walcott BP, Nahed BV, Kahle KT, et al. Deep brain stimulation for medically refractory life-threatening status dystonicus in children. J Neurosurg Pediatr 2012; 9:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honey CM, Malhotra AK, Tarailo-Graovac M, et al. GNAO1 Mutation-Induced Pediatric Dystonic Storm Rescue With Pallidal Deep Brain Stimulation. J Child Neurol 2018; 33:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogt LM, Yan H, Santyr B, et al. Deep Brain Stimulation for Refractory Status Dystonicus in Children: Multicenter Case Series and Systematic Review. Ann Neurol 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marras CE, Rizzi M, Cantonetti L, et al. Pallidotomy for medically refractory status dystonicus in childhood. Dev Med Child Neurol 2014; 56:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord 2005; 20:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999; 319:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derinoz O, Caglar AA. Drug-induced movement disorders in children at paediatric emergency department: 'dystonia'. Emerg Med J 2013; 30:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanburoglu MK, Derinoz O, Cizmeci MN, Havali C. Is acute dystonia an emergency? Sometimes, it really is! Pediatr Emerg Care 2013; 29:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978; 135:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother 2010; 10:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niemann N, Jankovic J. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol 2019; 42:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahone EM, Bridges D, Prahme C, Singer HS. Repetitive arm and hand movements (complex motor stereotypies) in children. J Pediatr 2004; 145:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs 2016; 76:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Péter Z, Oliphant ME, Fernandez TV. Motor Stereotypies: A Pathophysiological Review. Front Neurosci 2017; 11:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotia M, York MK, Strutt AM, Jankovic J. Leg stereotypy syndrome: phenomenology and prevalence. J Neurol Neurosurg Psychiatry 2018; 89:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016; 17:2461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh D, Rajan PV, Erenberg G. A comparative study of primary and secondary stereotypies. J Child Neurol 2013; 28:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleiss B, Gressens P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol 2012; 11:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eshel G, Lahat E, Azizi E, et al. Chorea as a manifestation of rheumatic fever--A 30-year survey (1960-1990). Eur J Pediatr 1993; 152:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardoso F, Vargas AP, Oliveira LD, et al. Persistent Sydenham's chorea. Mov Disord 1999; 14:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medlock MD, Cruse RS, Winek SJ, et al. A 10-year experience with postpump chorea. Ann Neurol 1993; 34:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunberg JA, Doty DB, Reilly EL. Choreoathetosis in infants following cardiac surgery with deep hypothermia and circulatory arrest. J Pediatr 1974; 84:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong PC, Barlow CF, Hickey PR, et al. Factors associated with choreoathetosis after cardiopulmonary bypass in children with congenital heart disease. Circulation 1992; 86:II118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           du Plessis AJ, Bellinger DC, Gauvreau K, et al. Neurologic outcome of choreoathetoid encephalopathy after cardiac surgery. Pediatr Neurol 2002; 27:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huntley DT, al-Mateen M, Menkes JH. Unusual dyskinesia complicating cardiopulmonary bypass surgery. Dev Med Child Neurol 1993; 35:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupsky WJ, Drozd MA, Barlow CF. Selective injury of the globus pallidus in children with post-cardiac surgery choreic syndrome. Dev Med Child Neurol 1995; 37:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thobois S, Bozio A, Ninet J, et al. Chorea after cardiopulmonary bypass. Eur Neurol 2004; 51:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergman I, Steeves M, Burckart G, Thompson A. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. J Pediatr 1991; 119:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane JC, Tennison MB, Lawless ST, et al. Movement disorder after withdrawal of fentanyl infusion. J Pediatr 1991; 119:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martich-Kriss V, Kollias SS, Ball WS Jr. MR findings in kernicterus. AJNR Am J Neuroradiol 1995; 16:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlman JM, Volpe JJ. Movement disorder of premature infants with severe bronchopulmonary dysplasia: a new syndrome. Pediatrics 1989; 84:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parnes M, Bashir H, Jankovic J. Is Benign Hereditary Chorea Really Benign? Brain-Lung-Thyroid Syndrome Caused by NKX2-1 Mutations. Mov Disord Clin Pract 2019; 6:34.
          </a>
         </li>
         <li class="breakAll">
          Patel NJ, Jankovic J. NKX2-1-Related Disorders.GeneReviews. www.ncbi.nlm.nih.gov/books/NBK185066/ (Accessed on April 25, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mencacci NE, Erro R, Wiethoff S, et al. ADCY5 mutations are another cause of benign hereditary chorea. Neurology 2015; 85:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrag A, Quinn NP, Bhatia KP, Marsden CD. Benign hereditary chorea--entity or syndrome? Mov Disord 2000; 15:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gras D, Jonard L, Roze E, et al. Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry 2012; 83:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong MJ, Shah BB, Chen R, et al. Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. Mov Disord 2011; 26:2296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peall KJ, Lumsden D, Kneen R, et al. Benign hereditary chorea related to NKX2.1: expansion of the genotypic and phenotypic spectrum. Dev Med Child Neurol 2014; 56:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willemsen MA, Breedveld GJ, Wouda S, et al. Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr 2005; 164:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carré A, Szinnai G, Castanet M, et al. Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case. Hum Mol Genet 2009; 18:2266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suchowersky O, Hayden MR, Martin WR, et al. Cerebral metabolism of glucose in benign hereditary chorea. Mov Disord 1986; 1:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuwert T, Lange HW, Langen KJ, et al. Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography. J Neurol 1990; 237:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology 2005; 64:1952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen DH, Méneret A, Friedman JR, et al. ADCY5-related dyskinesia: Broader spectrum and genotype-phenotype correlations. Neurology 2015; 85:2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carapito R, Paul N, Untrau M, et al. A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov Disord 2015; 30:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan JC, Kurek JA, Davis J, Sethi KD. ADCY5 mutations are another cause of benign hereditary chorea. Neurology 2016; 86:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang FC, Westenberger A, Dale RC, et al. Phenotypic insights into ADCY5-associated disease. Mov Disord 2016; 31:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Méneret A, Gras D, McGovern E, Roze E. Caffeine and the Dyskinesia Related to Mutations in the ADCY5 Gene. Ann Intern Med 2019; 171:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dy ME, Chang FC, Jesus SD, et al. Treatment of ADCY5-Associated Dystonia, Chorea, and Hyperkinetic Disorders With Deep Brain Stimulation: A Multicenter Case Series. J Child Neurol 2016; 31:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mak BS, Chi CS, Tsai CR, et al. New mutations of the HPRT gene in Lesch-Nyhan syndrome. Pediatr Neurol 2000; 23:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puig JG, Torres RJ, Mateos FA, et al. The spectrum of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Clinical experience based on 22 patients from 18 Spanish families. Medicine (Baltimore) 2001; 80:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jinnah HA, Ceballos-Picot I, Torres RJ, et al. Attenuated variants of Lesch-Nyhan disease. Brain 2010; 133:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jinnah HA, Visser JE, Harris JC, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006; 129:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elble R, Deuschl G. Milestones in tremor research. Mov Disord 2011; 26:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulcher JR, Jónsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet 1997; 17:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord 1998; 13:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics 2004; 114:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull M, Parnes M. Effective Treatment of Geniospasm: Case Series and Review of the Literature. Tremor Other Hyperkinet Mov (N Y) 2020; 10:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanasse M, Bedard P, Andermann F. Shuddering attacks in children: an early clinical manifestation of essential tremor. Neurology 1976; 26:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanazawa O. Shuddering attacks-report of four children. Pediatr Neurol 2000; 23:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balint B, Guerreiro R, Carmona S, et al. KCNN2 mutation in autosomal-dominant tremulous myoclonus-dystonia. Eur J Neurol 2020; 27:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996; 11:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kälviäinen R, Khyuppenen J, Koskenkorva P, et al. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008; 49:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sipilä JOT, Hyppönen J, Kytö V, Kälviäinen R. Unverricht-Lundborg disease (EPM1) in Finland: A nationwide population-based study. Neurology 2020; 95:e3117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyppönen J, Äikiä M, Joensuu T, et al. Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study. Neurology 2015; 84:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006; 47:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997; 386:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virtaneva K, D'Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 1997; 15:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pennacchio LA, Lehesjoki AE, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serratosa JM, Gardiner RM, Lehesjoki AE, et al. The molecular genetic bases of the progressive myoclonus epilepsies. Adv Neurol 1999; 79:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkovic SF, Mazarib A, Walid S, et al. A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain 2005; 128:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferlazzo E, Canafoglia L, Michelucci R, et al. Mild Lafora disease: clinical, neurophysiologic, and genetic findings. Epilepsia 2014; 55:e129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karimipour D, Lowe L, Blaivas M, et al. Lafora disease: diagnosis by skin biopsy. J Am Acad Dermatol 1999; 41:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesh S, Agarwala KL, Ueda K, et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet 2000; 9:2251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minassian BA, Ianzano L, Meloche M, et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 2000; 55:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 2003; 35:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohi H, Turnbull J, Zhao XC, et al. Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology 2007; 68:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan EM, Omer S, Ahmed M, et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 2004; 63:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turnbull J, Girard JM, Lohi H, et al. Early-onset Lafora body disease. Brain 2012; 135:2684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tijssen MA, Voorkamp LM, Padberg GW, van Dijk JG. Startle responses in hereditary hyperekplexia. Arch Neurol 1997; 54:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini AG, Pandey S. Hyperekplexia and other startle syndromes. J Neurol Sci 2020; 416:117051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiang R, Ryan SG, Zhu YZ, et al. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993; 5:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferraroli E, Perulli M, Veredice C, et al. Hereditary Hyperekplexia: A New Family and a Systematic Review of GLRA1 Gene-Related Phenotypes. Pediatr Neurol 2022; 132:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees MI, Lewis TM, Kwok JB, et al. Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). Hum Mol Genet 2002; 11:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piard J, Umanah GKE, Harms FL, et al. A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. Brain 2018; 141:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees MI, Harvey K, Pearce BR, et al. Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat Genet 2006; 38:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaes F, Fühlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012; 27:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013; 28:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hacohen Y, Dlamini N, Hedderly T, et al. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy. Dev Med Child Neurol 2014; 56:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammad SS, Fung VS, Grattan-Smith P, et al. Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord 2014; 29:1539.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6232 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Jankovic J, Hallet M, Okun M, et al. Principles and Practice of Movement Disorders, 3rd ed, Elsevier, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20589866" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Definition and classification of hyperkinetic movements in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34596744" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Self-injurious behavior in Tourette syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34596744" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Self-injurious behavior in Tourette syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759682" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of tic disorders: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27158458" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Provisional Tic Disorder: What to tell parents when their child first starts ticcing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30850688" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Provisional Tic Disorder is not so transient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34387394" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Rapid Onset Functional Tic-Like Behaviors in Young Females During the COVID-19 Pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33942911" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23649720" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Phenomenology and classification of dystonia: a consensus update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25395479" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25395479" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30237473" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15677703" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pathophysiological differences between musician's dystonia and writer's cramp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9549503" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Status dystonicus: the syndrome and its management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11921121" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2879237" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Brain neurotransmitters in dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9749595" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Functional brain networks in DYT1 dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31591783" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Ten-Year Reflections on the Neurophysiological Abnormalities of Focal Dystonias in Humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11784827" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35481685" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22190371" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Glut1 deficiency syndrome and erythrocyte glucose uptake assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24142590" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Treatment of dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24304390" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Status dystonicus: a practice guide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35253510" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Status Dystonicus in Children: A Cross-Sectional Study and Review of Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23893456" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Medical treatment of dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34840878" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pediatric Dystonic Storm: A Hospital-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21425339" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of a dystonic storm with pallidal stimulation in a patient with PANK2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19750494" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Deep brain stimulation in acute management of status dystonicus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20170298" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Successful bilateral deep brain stimulation of the globus pallidus internus for persistent status dystonicus and generalized chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22208329" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Deep brain stimulation for medically refractory life-threatening status dystonicus in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29661126" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : GNAO1 Mutation-Induced Pediatric Dystonic Storm Rescue With Pallidal Deep Brain Stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37714824" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Deep Brain Stimulation for Refractory Status Dystonicus in Children: Multicenter Case Series and Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24697701" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pallidotomy for medically refractory status dystonicus in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15390048" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Metoclopramide-induced tardive dyskinesia in an infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10473482" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Acute dystonia induced by drug treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22398848" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Drug-induced movement disorders in children at paediatric emergency department: 'dystonia'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23462398" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Is acute dystonia an emergency? Sometimes, it really is!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29498" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20518606" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tardive dyskinesia and withdrawal emergent syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30870235" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Real-World Experience With VMAT2 Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15343197" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Repetitive arm and hand movements (complex motor stereotypies) in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27091214" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28405185" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Motor Stereotypies: A Pathophysiological Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29332008" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Leg stereotypy syndrome: phenomenology and prevalence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27819145" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dopamine depleters in the treatment of hyperkinetic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23143719" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A comparative study of primary and secondary stereotypies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22608669" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8404967" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Chorea as a manifestation of rheumatic fever--a 30-year survey (1960-1990).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10495042" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Persistent Sydenham's chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8250531" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A 10-year experience with postpump chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4810730" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Choreoathetosis in infants following cardiac surgery with deep hypothermia and circulatory arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1423989" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Factors associated with choreoathetosis after cardiopulmonary bypass in children with congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12160967" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Neurologic outcome of choreoathetoid encephalopathy after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9435780" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Unusual dyskinesia complicating cardiopulmonary bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7851670" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Selective injury of the globus pallidus in children with post-cardiac surgery choreic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14639031" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Chorea after cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919899" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919900" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Movement disorder after withdrawal of fentanyl infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207355" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Neonatal hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7611048" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : MR findings in kernicterus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2748247" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Movement disorder of premature infants with severe bronchopulmonary dysplasia: a new syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30746413" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Is Benign Hereditary Chorea Really Benign? Brain-Lung-Thyroid Syndrome Caused by NKX2-1 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30746413" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Is Benign Hereditary Chorea Really Benign? Brain-Lung-Thyroid Syndrome Caused by NKX2-1 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26085604" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : ADCY5 mutations are another cause of benign hereditary chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10752577" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Benign hereditary chorea--entity or syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22832740" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714005" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24171694" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Benign hereditary chorea related to NKX2.1: expansion of the genotypic and phenotypic spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15517377" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336474" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2973557" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cerebral metabolism of glucose in benign hereditary chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2141358" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15955952" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26537056" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : ADCY5-related dyskinesia: Broader spectrum and genotype-phenotype correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25545163" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26952302" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : ADCY5 mutations are another cause of benign hereditary chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27061943" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Phenotypic insights into ADCY5-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31181574" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Caffeine and the Dyskinesia Related to Mutations in the ADCY5 Gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27052971" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Treatment of ADCY5-Associated Dystonia, Chorea, and Hyperkinetic Disorders With Deep Brain Stimulation: A Multicenter Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11068166" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : New mutations of the HPRT gene in Lesch-Nyhan syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11307586" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The spectrum of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Clinical experience based on 22 patients from 18 Spanish families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20176575" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Attenuated variants of Lesch-Nyhan disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549399" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Delineation of the motor disorder of Lesch-Nyhan disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21626554" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Milestones in tremor research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9288103" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Mapping of a familial essential tremor gene, FET1, to chromosome 3q13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827627" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Evidence that a gene for essential tremor maps to chromosome 2p in four families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15520096" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Essential tremor among children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32874771" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effective Treatment of Geniospasm: Case Series and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/988508" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Shuddering attacks in children: an early clinical manifestation of essential tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11118798" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Shuddering attacks-report of four children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32212350" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : KCNN2 mutation in autosomal-dominant tremulous myoclonus-dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8684380" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Essential myoclonus and myoclonic dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325013" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Clinical picture of EPM1-Unverricht-Lundborg disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32943486" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Unverricht-Lundborg disease (EPM1) in Finland: A nationwide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25770194" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16686650" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9126745" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9090386" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8596935" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10514828" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The molecular genetic bases of the progressive myoclonus epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15634728" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25270369" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Mild Lafora disease: clinical, neurophysiologic, and genetic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10534649" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Lafora disease: diagnosis by skin biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11001928" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10932264" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12958597" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Mutations in NHLRC1 cause progressive myoclonus epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17389303" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15304597" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22961547" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Early-onset Lafora body disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9109739" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Startle responses in hereditary hyperekplexia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32721683" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Hyperekplexia and other startle syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8298642" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35636282" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Hereditary Hyperekplexia: A New Family and a Systematic Review of GLRA1 Gene-Related Phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929858" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29390050" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751771" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15136676" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15988749" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22555904" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Movement disorders in autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23400857" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The spectrum of movement disorders in children with anti-NMDA receptor encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24127856" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25154478" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
